PLI Push Drives ₹5,210 Crore Investment in Bulk Drugs, Strengthening India’s API Manufacturing Base
India’s Production Linked Incentive (PLI) Scheme for Bulk Drugs is emerging as a key policy instrument for strengthening domestic pharmaceutical manufacturing, with total investment reaching ₹5,210.74 crore as of June 2026. The investment has exceeded the committed level of ₹4,330 crore, reflecting stronger-than-targeted capital deployment in critical pharmaceutical inputs.
Approved in 2020 with a financial outlay of ₹6,940 crore, the scheme aims to promote domestic manufacturing of 41 identified critical Key Starting Materials (KSMs), Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs). A total of 48 projects have been approved, while 39 projects covering 28 APIs/KSMs have been commissioned.
The policy is also expanding India’s capacity in strategically important fermentation-based products. Domestic manufacturing of Penicillin-G, Clavulanic Acid and Rifampicin has gained momentum under the programme, areas where India had earlier faced significant import dependence. Beneficiary companies recorded cumulative sales of ₹3,792.49 crore by June 2026, including exports worth ₹560.16 crore, while generating employment for around 5,127 people.
Why It Matters: The investment signals a broader shift towards building an integrated pharmaceutical supply chain within India. Increased domestic production of APIs and other critical inputs can improve supply security, support backward integration and strengthen resilience against global supply disruptions. The commissioning of new greenfield facilities also creates scope for greater domestic value addition and technology adoption.
The government’s latest data indicates that the Bulk Drugs PLI is moving beyond financial incentives towards building long-term manufacturing capacity in strategically important pharmaceutical segments, supporting the broader objectives of Make in India and Atmanirbhar Bharat.
